Abstract
White-coat hypertension is characterized by an elevation in clinic blood pressure but normal home or ambulatory blood-pressure values, whereas patients with masked hypertension have normal clinic blood pressure and elevated ambulatory or home blood-pressure load. Both white-coat and masked hypertension are frequent clinical entities that need appropriate recognition and a close diagnostic follow-up. White-coat and masked hypertension seem to be associated with organ damage and increased cardiovascular risk, although not invariably. In addition, patients with masked or white-coat hypertension have an increased risk of abnormalities affecting their glucose and lipid profiles. Therefore, the diagnosis of these conditions should be accurate and include the assessment of cardiovascular as well as of metabolic risk. Once diagnosed, first-line therapeutic interventions should be nonpharmacological and aim at lifestyle changes, but drug treatment can be indicated, particularly when the patient's cardiovascular risk profile is elevated or when target-organ damage is detected.
Key Points
-
White-coat and masked hypertension are frequently seen in current clinical practice and are often characterized by the presence of subclinical organ damage and metabolic abnormalities
-
The pathophysiological mechanisms responsible for these conditions are still largely unknown, although a sympathetic activation is common in both these hypertensive states
-
White-coat and masked hypertension cannot be regarded as clinically benign; masked hypertension, in particular, is associated with increased cardiovascular risk and mortality
-
The cardiovascular risk profile of patients with white-coat or masked hypertension should be carefully monitored, and lifestyle interventions should be adopted early in the clinical course of disease
-
Antihypertensive drug treatment should be initiated, particularly in the case of elevated cardiovascular risk, target-organ damage, or both
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mancia, G. et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of European Society of Cardiology (ESC). J. Hypertens. 25, 1105–1187 (2007).
Chobanian, A. V. et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42, 1206–1252 (2003).
Riva-Rocci, S. Un nuovo sfigmomanometro [Italian]. Gazzetta Medica di Torino 50, 981–996 (1896).
Ayman, D. & Goldshine, A. D. Blood pressure determinations by patients with essential hypertension: the difference between clinic and home readings before treatment. Am. J. Med. Sci. 200, 465–470 (1940).
Mancia, G. et al. Effects of blood-pressure measurement by the doctor on patient's blood pressure and heart rate. Lancet 2, 695–698 (1983).
Mancia, G., Di Rienzo, M. & Parati, G. Ambulatory blood pressure monitoring in hypertension research and clinical practice. Hypertension 21, 510–524 (1993).
Mancia, G. et al. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension 9, 209–215 (1987).
Parati, G. et al. Difference between clinic and daytime blood pressure is not a measure of the white coat effect. Hypertension 31, 1185–1189 (1998).
Parati, G. et al. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J. Hypertens. 26, 1505–1526 (2008).
Sega, R. et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) Study). Circulation 104, 1385–1392 (2001).
Pickering, T. G. et al. How common is white coat hypertension? JAMA 259, 225–228 (1988).
Julius, S. et al. “White coat” versus “sustained” borderline hypertension in Tecumseh, Michigan. Hypertension 16, 617–623 (1990).
Mancia, G. et al. Long-term risk of mortality associated with selective and combined elevation in office, home and ambulatory blood pressure. Hypertension 47, 846–853 (2006).
McManus, R. J. et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet 376, 163–172 (2010).
Verdecchia, P. et al. Independent predictors of isolated clinic ('white-coat') hypertension. J. Hypertens. 19, 1015–1020 (2001).
Hegholm, A. et al. White-coat hypertension diagnosed by 24-h ambulatory monitoring. Estimation of 159 newly diagnosed hypertensive patients. Am. J. Hypertens. 5, 64–70 (1992).
Lindbaek, M. et al. Predictors of white-coat effect in general practice patients with suspected and tertaed hypertension. Br. J. Gen. Pract. 53, 790–793 (2003).
Dolan, E. et al. Determinants of white-coat hypertension. Blood Press. Monit. 9, 307–309 (2004).
Streitel, K. l. et al. Explaining gender differences in the white coat effect. Blood Press. Monit. 16, 1–6 (2011).
Agyemang, C., Bhopal, R., Bruijnzeels, M. & Redekop, W. K. Does the white-coat effect in people of African and South Asian descent differ from that in White people of European origin? A systematic review and meta-analysis. Blood Press. Monit. 10, 243–248 (2005).
Labinson, P. T., Giacco, S., Gift, H., Mansoor, G. A. & White, W. B. The importance of the clinical observer in the development of a white-coat effect in African-American patients with hypertension. Blood Press. Monit. 13, 139–142 (2008).
Sega, R. et al. Ambulatory and home blood pressure normality in the elderly: data from the PAMELA population. Hypertension 30, 1–6 (1997).
Schillaci, G. et al. Combined effect of office and 24-h blood pressure on aortic stiffness in human hypertension. J. Hypertens. 29, 869–875 (2011).
Zakopoulos, N. A. et al. White-coat effect in normotension and hypertension. Blood Press. Monit. 7, 271–276 (2002).
Mancia, G. et al. Twenty-four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study. J. Hypertens. 19, 1755–1763 (2001).
Grassi, G. & Esler, M. How to assess sympathetic activity in humans. J. Hypertens. 17, 719–734 (1999).
Grassi, G., Turri, C., Vailati, S., Dell'Oro, R. & Mancia, G. Muscle and skin sympathetic nerve traffic during the white-coat effect. Circulation 100, 222–225 (1999).
Ogedegbe, G. et al. The misdiagnosis of hypertension: the role of patient anxiety. Arch. Intern. Med. 168, 2459–2465 (2008).
Parati, G. et al. Comparison of the cardiovascular effects of different laboratory stressors and their relationship with blood pressure variability. J. Hypertens. 6, 481–488 (1988).
Smith, P. A., Graham, L. N., Mackintosh, A. F., Stoker, J. B. & Mary, D. A. Relationship between central sympathetic activity and stages of human hypertension. Am. J. Hypertens. 17, 217–222 (2004).
Grassi, G. et al. Neurogenic abnormalities in masked hypertension. Hypertension 50, 537–542 (2007).
Grassi, G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension 54, 690–697 (2009).
Curgunlu, A. et al. Increased circulating concentrations of asymmetric dimethylarginine (ADMA) in white coat hypertension. J. Hum. Hypertens. 19, 629–633 (2005).
Mancia, G. & Zanchetti, A. White-coat hypertension: misnomers, misconceptions and misunderstandings. What should we do next? J. Hypertens. 14, 1049–1052 (1996).
Mancia, G. White coat effect. Innocuous or adverse phenomenon? Eur. Heart J. 21, 1647–1648 (2000).
Pall, D. et al. Assessment of target-organ damage in adolescent white-coat and sustained hypertensives. J. Hypertens. 28, 2139–2144 (2010).
Nakashima, T. et al. White-coat hypertension contributes to the presence of carotid arteriosclerosis. Hypertens. Res. 27, 739–745 (2004).
Puato, M. et al. Increase in carotid intima-media thickness in grade I hypertensive subjects. White-coat versus sustained hypertension. Hypertension 51, 1300–1305 (2008).
Palatini, P. et al. Target organ damage in stage I hypertensive subjects with white coat and sustained hypertension. Results from the HARVEST study. Hypertension 32, 377–378 (1998).
Mancia, G. et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension 54, 226–232 (2009).
Bombelli, M. et al. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. J. Hypertens. 27, 2458–2464 (2009).
Kostis, V. et al. Target organ damage in white-coat and masked hypertension. Am. J. Hypertens. 21, 393–399 (2008).
Pose-Reino, A. et al. Diagnostic criteria of white coat hypertension (WCH): consequences for the implications of WCH for target organs. Blood Press. 11, 144–150 (2002).
Stabouli, S. et al. White-coat and masked hypertension in children: association with target-organ damage. Pediatr Nephrol. 20, 1151–1155 (2005).
Verdecchia, P. et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 24, 793–801 (1994).
Verdecchia, P. et al. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension 45, 203–208 (2005).
Pierdomenico, S. D., Lapenna, D., Di Mascio, R. & Cuccurullo, F. Short- and long-term risk of cardiovascular events in white-coat hypertension. J. Hum. Hypertens. 22, 408–414 (2008).
Hansen, T. W., Jeppesen, J., Rasmussen, S., Ibsen, H. & Torp-Pedersen, C. Ambulatory blood pressure monitoring and risk of cardiovascular disease: a population based study. Am. J. Hypertens. 19, 243–250 (2006).
Kario, K. et al. Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. J. Am. Coll. Cardiol. 38, 238–245 (2001).
Fagard, R. H., van den Broeke, C. & de Cort, P. Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice. J. Hum. Hypertens. 19, 801–807 (2005).
Ohkubo, T. et al. Prognosis of “masked” hypertension and “white-coat” hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J. Am. Coll. Cardiol. 46, 508–515 (2005).
Bobrie, G. et al. Cardiovascular prognosis of “masked hypertension” detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 291, 1342–1349 (2004).
Fagard, R. H. & Cornelissen, V. A. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J. Hypertens. 25, 2193–2198 (2007).
Gustavsen, P. H., Høegholm, A., Bang, L. E. & Kristensen, K. S. White coat hypertension is a cardiovascular risk factor: A 10-year follow-up study. J. Hum. Hypertens. 17, 811–817 (2003).
Mancia, G. et al. Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. J. Hypertens. 27, 1672–1678 (2009).
Sega, R. et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 111, 1777–1783 (2005).
Dolan, E. et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 46, 156–161 (2005).
Weber, M. A., Neutel, J. M., Smith, D. H. & Graettinger, W. F. Diagnosis of mild hypertension by ambulatory blood pressure monitoring. Circulation 90, 2291–2298 (1994).
Mancia, G. et al. Long-term prognostic value of blood pressure variability in the general population: results of the Pressioni Arteriose Monitorate e Loro Associazioni Study. Hypertension 49, 1265–1270 (2007).
Sander, D., Kukla, C., Klingelhöfer, J., Winbeck, K. & Conrad, B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: a 3-year follow-up study. Circulation 102, 1536–1541 (2000).
Kikuya, M. et al. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. Hypertension 36, 901–906 (2000).
Pringle, E. et al. Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. J. Hypertens. 21, 2251–2257 (2003).
Pickering, T. G. The ninth Sir George Pickering memorial lecture: ambulatory blood pressure monitoring and the definition of hypertension. J. Hypertens. 10, 401–409 (1992).
Selenta, C., Hogan, B. E. & Linden, W. How often do office blood pressure measurements fail to identify true hypertension? An exploration of white-coat normotension. Arch. Fam. Med. 9, 533–540 (2000).
Palatini, P. Masked hypertension. How can the condition be detected? Blood Press. Monit. 9, 297–299 (2004).
Papadopoulos, D. P. & Makris, T. K. Masked hypertension definition, impact, outcomes: a critical review. J. Clin. Invest. 9, 956–963 (2007).
Schnall, P. l., Schwartz, J. E., Landsbergis, P. A., Warren, K. & Pickering, T. G. Relation between job strain, alcohol and ambulatory blood pressure. Hypertension 19, 488–494 (1992).
Mann, S. J., James, G. D., Wang, R. S. & Pickering, T. G. Elevation of ambulatory systolic blood pressure in hypertensive smokers. A case-control study. JAMA 265, 2226–2228 (1991).
Liu, J. E. et al. Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure. Ann. Intern. Med. 131, 564–572 (1999).
Pierdomenico, S. D. et al. Prognostic relevance of masked hypertension in subjects with prehypertension. Am. J. Hypertens. 21, 879–883 (2008).
Björklund, K., Lind, L., Zethelius, B., Andrén, B. & Lithell, H. Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men. Circulation 107, 1297–1302 (2003).
Fagard, R. H. et al. Relationship between ambulatory blood pressure and follow-up clinic blood pressure in elderly patients with systolic hypertension. J. Hypertens. 22, 81–87 (2004).
Staessen, J. A. et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 282, 539–546 (1999).
Mancia, G. & Parati, G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis. J. Hypertens. 22, 435–445 (2004).
Mancia, G. Effective ambulatory blood pressure control in medical practice: good news to be taken with caution. Hypertension 49, 17–18 (2007).
Author information
Authors and Affiliations
Contributions
M. Bombelli and G. Seravalle researched data for the article and provided a substantial contribution to the discussion of content. G. Mancia and G. Grassi wrote the article and reviewed and edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Mancia, G., Bombelli, M., Seravalle, G. et al. Diagnosis and management of patients with white-coat and masked hypertension. Nat Rev Cardiol 8, 686–693 (2011). https://doi.org/10.1038/nrcardio.2011.115
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2011.115
This article is cited by
-
Continuous cuffless blood pressure monitoring with a wearable ring bioimpedance device
npj Digital Medicine (2023)
-
Home blood pressure monitors owned by participants in a large decentralised clinical trial in hypertension: the Treatment In Morning versus Evening (TIME) study
Journal of Human Hypertension (2022)
-
Factors influencing home blood pressure monitor ownership in a large clinical trial
Journal of Human Hypertension (2022)
-
Effect of physician attire on patient perceptions of empathy in Japan: a quasi-randomized controlled trial in primary care
BMC Family Practice (2021)
-
Differences in prevalence of hypertension subtypes according to the 2018 Korean Society of Hypertension and 2017 American College of Cardiology/American Heart Association guidelines: The Korean National Health and Nutrition Examination Survey, 2007–2017 (KNHANES IV-VII)
Clinical Hypertension (2019)